Literature DB >> 17675502

Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity.

Chen Xu1, Jianhua Sui, Hong Tao, Quan Zhu, Wayne A Marasco.   

Abstract

The chemokine receptor CXCR4 and its ligand stromal-derived factor-1 (SDF-1/CXCL12) are essential for many biological processes and various pathological conditions. However, the relationship between CXCR4 antigenic structure and SDF-1-mediated biological responses is poorly understood. In this report, a panel of human anti-CXCR4 Abs were isolated and used to explore CXCR4 antigenic heterogeneity and function. Multiple fixed CXCR4 antigenic isoforms were detected on the surface of hemopoietic cells. Epitope mapping studies demonstrated the complex nature of the surface-exposed CXCR4 epitopes. Ab-mediated inhibition of chemotaxis correlated strongly with binding affinity, epitope recognition, as well as the level of CXCR4 isoform expression. In addition, detailed genetic analyses of these Abs showed evidence of V(H) replacement. Importantly, structural and biochemical studies demonstrated tyrosine sulfation in novel regions of the V genes that contributed bidirectionally to the binding activity of the Abs. These data provide the first evidence that functional tyrosine sulfation occurs in self-reactive Abs and suggest a potential new mechanism that may contribute to the pathogenesis of Ab-mediated autoimmune disease. These Abs also provide valuable tools to explore the selective in vivo targeting of CXCR4 isoforms that may be preferentially expressed in certain disease states and involved in steady-state CXCR4-SDF-1 homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675502     DOI: 10.4049/jimmunol.179.4.2408

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Authors:  Sven Jähnichen; Christophe Blanchetot; David Maussang; Maria Gonzalez-Pajuelo; Ken Y Chow; Leontien Bosch; Sindi De Vrieze; Benedikte Serruys; Hans Ulrichts; Wesly Vandevelde; Michael Saunders; Hans J De Haard; Dominique Schols; Rob Leurs; Peter Vanlandschoot; Theo Verrips; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 2.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

3.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Authors:  Xian-Chun Tang; Sudhakar S Agnihothram; Yongjun Jiao; Jeremy Stanhope; Rachel L Graham; Eric C Peterson; Yuval Avnir; Aimee St Clair Tallarico; Jared Sheehan; Quan Zhu; Ralph S Baric; Wayne A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

5.  Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.

Authors:  Chen Xu; Agnes Lo; Anuradha Yammanuru; Aimee St Clair Tallarico; Kristen Brady; Akikazu Murakami; Natasha Barteneva; Quan Zhu; Wayne A Marasco
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

6.  An activation-induced cytidine deaminase-independent mechanism of secondary VH gene rearrangement in preimmune human B cells.

Authors:  Nancy S Longo; Gabrielle J Grundy; Jisoo Lee; Martin Gellert; Peter E Lipsky
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

7.  Molecular basis for the antagonistic activity of an anti-CXCR4 antibody.

Authors:  Li Peng; Melissa M Damschroder; Kimberly E Cook; Herren Wu; William F Dall'Acqua
Journal:  MAbs       Date:  2016       Impact factor: 5.857

8.  Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway.

Authors:  Jianhua Sui; Daniel R Aird; Azaibi Tamin; Akikazu Murakami; Meiying Yan; Anuradha Yammanuru; Huaiqi Jing; Biao Kan; Xin Liu; Quan Zhu; Qing-An Yuan; Gregory P Adams; William J Bellini; Jianguo Xu; Larry J Anderson; Wayne A Marasco
Journal:  PLoS Pathog       Date:  2008-11-07       Impact factor: 6.823

9.  Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles.

Authors:  Ran Taube; Quan Zhu; Chen Xu; Felipe Diaz-Griffero; Jianhua Sui; Erick Kamau; Markryan Dwyer; Daniel Aird; Wayne A Marasco
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

10.  Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.

Authors:  Urs B Hagemann; Lavinia Gunnarsson; Solène Géraudie; Ulrike Scheffler; Remko A Griep; Herald Reiersen; Alexander R Duncan; Sergej M Kiprijanov
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.